In the context of available literature, our study is the first to provide evidence for the superior efficacy of checkpoint inhibitor-based combinations compared with ICIs monotherapy and other anticancer therapy in NSCLC patients who experienced disease progression after treatment with PD-1/PD-L1 inhibitors in clinical practice. Here, CD274 is linked to non-small cell lung carcinoma.